TRAIL receptors in the serum of patients with B-cell chronic lymphocytic leukemia.

[Guest guest]

TRAIL receptors in the serum of patients with B-cell chronic lymphocytic

leukemia.

E Jablonska, B Kiersnowska-Rogowska, M Aleksandrowicz-Bukin, F Rogowski, and J

Sawicka-Powierza

Neoplasma, January 1, 2008; 55(1): 51-4.

Great importance in the course of chronic B-cell lymphocytic leukemia (B-CLL)

has been ascribed to cytokines belonging to the superfamily of the tumor

necrosis factor (TNF), including TRAIL (TNF-related apoptosis inducing ligand)

and its specific receptors: TRAIL receptor 1 (TRAIL-R1), TRAIL receptor 2

(TRAIL-R2), TRAIL receptor 3 (TRAIL-R3), TRAIL receptor 4 (TRAIL-R4) and

osteoprotegerin (OPG). Both the molecule and the receptors may occur in membrane

and soluble forms, except for OPG which has only a soluble form. The aim of the

study was to assess the levels of sTRAIL molecule and soluble TRAIL receptors -

sTRAIL-R2 and OPG in the serum of patients with B-CLL. The findings revealed

reduced concentrations of sTRAIL both before and after treatment and elevated

levels of sTRAIL-R2 and OPG in patients before treatment. After treatment with

CC (2CdA/Cladrybin and Cyklofosfamid) and FC (Fludarabin and Cyklofosfamid) we

observed an increase in sTRAIL and a decrease in sTRAIL-R2. OPG levels were

found to increase after treatment with CHOP (Vincristini, Cyklofosfamid,

Adriamycin and Prednisol) and they decreased after administration of Leukeran

(Chlorambucyl) and CMC (2CdA/Cladrybin, Mitoxanton and Cyklofosfamid). The

relationships between TRAIL and its natural regulators in the serum of BCLL

patients prior to treatment may impair apoptosis of leukemic B cells. Changes in

these relationships after treatment with CC and FC seem to promote enhancement

of apoptosis in these cells.

PMID: 18190241